Vol.

No.

January 03, 2020Jan 03, 2020

DOWNLOAD THE PDF

Cover Story

FDA guidance restricts e-cigarette flavors, leaving tobacco and menthol on the market

By Alexandria Carolan and Matthew Bin Han Ong

FDA Jan. 2 issued a final guidance that will restrict the sale of e-cigarette flavors most popular with minors.

Free Guest Editorial

FDA e-cigarette flavoring ban leaves a bad taste
“Trump eroding role of science in government”

By Alan Blum

Pazdur on the challenge of approving drugs for small indications
ODAC recommends approval for tazemetostat in rare sarcoma, sNDAs for Lynparza, Keytruda

By Paul Goldberg

Moffitt CEO Alan List, director Thomas Sellers resign over conflicts of interests involving China

By Matthew Bin Han Ong

Trump approves $212.5M increase to improve NCI success rates; FY20 spending bills provide new funding for childhood cancer, raise tobacco-purchase age to 21

By Alexandria Carolan and Matthew Bin Han Ong

Fox Chase acquired by Jefferson in definitive agreement with Temple

By Matthew Bin Han Ong

In Brief

HHS proposes plan to import cheaper drugs from Canada

Vokes elected ASCO president for 2021-22

Hahn sworn in as FDA commissioner

Fred Hutch receives $13M SPORE for immunotherapy, lung cancer research

Mt. Sinai receives $10M in NIH funding for brain tumor research

Ten oncology practices in underserved communities receive ASCO funding to participate in quality improvement programs

PharmaMar and Jazz Pharmaceuticals sign license agreement for lurbinectedin in U.S.

Clinical Roundup

NCCN pediatric cancer guidelines focus on improving long-term outcomes worldwide

SWOG study focuses on impact of vitamin and antioxidant supplement use in cancer patients

DREAMM-2 demonstrates meaningful ORR with belantamab mafodotin in multiple myeloma

Drugs & Targets

FDA approves Lynparza as first-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer

FDA approves Xtandi for metastatic castration-sensitive prostate indication

FDA approves treatment for patients with HER2-positive breast cancer who have progressed on available therapies

FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer

FDA grants Avatrombopag Orphan Drug Designation for chemotherapy-induced thrombocytopenia

Karyopharm submits NDA for Xpovio for relapsed or refractory diffuse large B-cell lymphoma

Amgen and Allergan submit BLA for biosimilar candidate to Rituxan

China approves Zejula as maintenance therapy for recurrent ovarian cancer

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 46 - December 19, 2025